organization · Reporting owner
Domicilium Real Estate Fund III LP
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180 | 10% owner | June 10, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eloxx Pharmaceuticals, Inc.
Report date June 10, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stock, $0.01 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 238,422 |
Reported balance
After 2026-06-10 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-06-10 · Other · Acquired 238,422 · Balance 238,422 F1: Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. F2: The securities are owned directly by Domicilium Real Estate Fund III LP (the "Fund") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner. |
| common stock, $0.01 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 361,578 |
Reported balance
After 2026-06-10 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-06-10 · Other · Acquired 361,578 · Balance 361,578 F1: Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. F3: The securities are owned directly by BKJLAGG, LLC ("BKJLAGG") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium. |
| common stock, $0.01 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 14,285 |
Reported balance
Holding disclosure · report date 2026-06-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 14,285 F4: The securities may be deemed to be indirectly beneficially owned by (i) Domicilium, and (ii) Daniel Simon, the managing member of Domicilium. |
| Pre-funded WarrantSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-06-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-10 · Other · Acquired 238,422 · Balance 0 F5: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F1: Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. F2: The securities are owned directly by Domicilium Real Estate Fund III LP (the "Fund") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner. |
| Pre-funded WarrantSEC Table II · derivative / convertible security | IndirectSee footnote | 834,489 |
Reported balance
After 2026-06-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-10 · Other · Acquired 361,578 · Balance 834,489 F5: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F1: Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. F3: The securities are owned directly by BKJLAGG, LLC ("BKJLAGG") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium. |
| Pre-funded WarrantSEC Table II · derivative / convertible security | IndirectSee footnote | 361,578 |
Reported balance
Holding disclosure · report date 2026-06-10 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 361,578 F5: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F6: The securities are owned directly by MSEK Charleston LLC ("MSEK") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to MSEK, and (ii) Daniel Simon, the managing member of Domicilium. |
| Pre-funded WarrantSEC Table II · derivative / convertible security | IndirectSee footnote | 611,317 |
Reported balance
Holding disclosure · report date 2026-06-10 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 611,317 F5: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F7: The securities are owned directly by Bold Stroke Investments, LLC ("Bold Stroke") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to Bold Stroke, and (ii) Daniel Simon, the managing member of Domicilium. |
Filing footnotes · ownership attribution and instrument terms
F1: Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock.
F2: The securities are owned directly by Domicilium Real Estate Fund III LP (the "Fund") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner.
F3: The securities are owned directly by BKJLAGG, LLC ("BKJLAGG") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium.
F4: The securities may be deemed to be indirectly beneficially owned by (i) Domicilium, and (ii) Daniel Simon, the managing member of Domicilium.
F5: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.
F6: The securities are owned directly by MSEK Charleston LLC ("MSEK") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to MSEK, and (ii) Daniel Simon, the managing member of Domicilium.
F7: The securities are owned directly by Bold Stroke Investments, LLC ("Bold Stroke") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to Bold Stroke, and (ii) Daniel Simon, the managing member of Domicilium.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 17, 2026 21:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | OtherPre-funded Warrant · Derivative | 361,578 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-26-004021 · ownership.xml · derivative · entry 5 Domicilium Real Estate Fund III LP · CIK 0001945896 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 834,489 Underlying: common stock, $0.01 par value per share · 361,578 shares Expires not disclosed F5 · derivative.exercise_price: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F1 · kind: Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. F5 · price: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F5 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F5 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F3 · ownership.nature: The securities are owned directly by BKJLAGG, LLC ("BKJLAGG") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium. Read SEC document |
| June 10, 2026 Filed Jun 17, 2026 21:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | OtherPre-funded Warrant · Derivative | 238,422 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-26-004021 · ownership.xml · derivative · entry 4 Domicilium Real Estate Fund III LP · CIK 0001945896 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: common stock, $0.01 par value per share · 238,422 shares Expires not disclosed F5 · derivative.exercise_price: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F1 · kind: Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. F5 · price: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F5 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F5 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F2 · ownership.nature: The securities are owned directly by Domicilium Real Estate Fund III LP (the "Fund") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner. Read SEC document |
| June 10, 2026 Filed Jun 17, 2026 21:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Othercommon stock, $0.01 par value per share | 361,578 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-26-004021 · ownership.xml · nonDerivative · entry 2 Domicilium Real Estate Fund III LP · CIK 0001945896 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 361,578 F1 · kind: Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. F1 · price: Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. F3 · ownership.nature: The securities are owned directly by BKJLAGG, LLC ("BKJLAGG") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium. Read SEC document |
| June 10, 2026 Filed Jun 17, 2026 21:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Othercommon stock, $0.01 par value per share | 238,422 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-26-004021 · ownership.xml · nonDerivative · entry 1 Domicilium Real Estate Fund III LP · CIK 0001945896 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 238,422 F1 · kind: Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. F1 · price: Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock. F2 · ownership.nature: The securities are owned directly by Domicilium Real Estate Fund III LP (the "Fund") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner. Read SEC document |
| May 27, 2026 Filed Jun 5, 2026 14:44 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | OtherPre-funded Warrant · Derivative | 113,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-26-003845 · ownership.xml · derivative · entry 3 Domicilium Real Estate Fund III LP · CIK 0001945896 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,422 Underlying: Common Stock, $0.01 par value per share · 113,636 shares Expires not disclosed F5 · derivative.exercise_price: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F1 · kind: Pursuant to the terms of the pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants"), Domicilium Real Estate Fund III LP (the "Fund"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer. F2 · shares: These securities reflect a 11 for 1 reverse stock split effective May 29, 2026. F5 · price: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F5 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F5 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F2 · derivative.underlying_shares: These securities reflect a 11 for 1 reverse stock split effective May 29, 2026. F2 · balance_after: These securities reflect a 11 for 1 reverse stock split effective May 29, 2026. F3 · ownership.direct: The securities are owned directly by the Fund and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium") the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (iii) Daniel Simon, the managing member of Domicilium and the General Partner. Read SEC document |
| May 27, 2026 Filed Jun 5, 2026 14:44 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | OtherCommon Stock, $0.01 par value per share | 113,636 | $0.00 | $0.00 |
DisclosureSEC source: 0000919574-26-003845 · ownership.xml · nonDerivative · entry 1 Domicilium Real Estate Fund III LP · CIK 0001945896 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the terms of the pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants"), Domicilium Real Estate Fund III LP (the "Fund"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer. F2 · shares: These securities reflect a 11 for 1 reverse stock split effective May 29, 2026. F3 · ownership.direct: The securities are owned directly by the Fund and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium") the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (iii) Daniel Simon, the managing member of Domicilium and the General Partner. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.